We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > lung injury

News List

FDA Grants IND Approval for Phase II Clinical Trial Using Stemedica's itMSC Therapy for COVID-19 Patients prnewswire
September 30, 2020
Stemedica Cell Technologies, Inc. has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) approval for "A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety ...
Biohaven to Proceed with Intranasal Vazegepant Trial for COVID-19 Lung Inflammation americanpharmaceuticalreview
April 14, 2020
Biohaven Pharmaceutical announced it submitted Pre-IND/IND material to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 study of vazegepant.
Windtree to Pursue Clinical Study of Lung Injury Treatment in COVID-19 Patients americanpharmaceuticalreview
March 25, 2020
Windtree Therapeutics announced it is planning to study its proprietary KL4 surfactant to potentially mitigate the pulmonary effects of severe COVID-19 infection.